|
|
Post by LosingMyBullishness on Feb 13, 2016 18:47:55 GMT -5
The TASE maneuver diluted the US stock since it was ordinary common stock that was sold. It was a good plan but incredibly badly executed. The TASE deal didn't work out but I don't see how it diluted the US market since there were no new shares offered. If I'm not mistaken the total outstanding shares remained the same. This is also what I took away as the original plan: They wanted to sell directly to TASE biotech funds with these funds not being allowed to sell into the US market. So the plan was not to dilute the US market. |
|
|
|
Post by LosingMyBullishness on Feb 13, 2016 18:57:43 GMT -5
I do not see any parallel between TASE and RLS. TASE was a plan to get cash without dilusion of US stocks. It did not worked out but that is often so in real life. Everyone would have cheered about the brilliance of the plan if it had succeeded. Why it did not succeed? This loophole had been used several times and Israli regulators decided that this time they play hardball. They did so basically in the last second (last day if I remember correctly) and as it seems without warning to MNKD management. 'Might' be that someone at Wall street asked them for this favour and this group was stronger than the old ties that Al had. I always thought that this was his last stunt. After that we did not hear much from him anymore. The TASE maneuver diluted the US stock since it was ordinary common stock that was sold. It was a good plan but incredibly badly executed. Why was it incredibly badly executed? It did not work well, sure. But why do you blame management. Everything was fine.They went down to Israel, finished paper work, had their speeches and when everyone thought it is done, the regulators stepped in. Then there was, I guess, some panic and last minute arrangements to save face. The issue was the late decision of the regulators. And there was a AF twitter message with a false translation of an article that was later lost.. |
|
|
|
Post by LosingMyBullishness on Feb 13, 2016 19:55:15 GMT -5
Let me be very clear. The RLS deal is simply a proof of concept deal. RSL wants to see if TS works for one or possibly a few of their drugs. Because no one knows what milestones actually means money for MNKD, this deal is just like the other deals Mannkind struck back in 2014 that didn't have any up front money and were all based on milestone payments. To date, those two deals have amounted to nothing. So while some of you want to feel good about your investigative skills, let me remind you that the odds of Mannkind making anything from the RSL deal are very low. If RLS thought technosphere was the game changer that many of you think it is, it would have proved it by giving MNKD up front cash. Many on here need to stop fooling yourselves. Unfortunately, it is quite obvious that you enjoy doing so. So you are the one that truly understands RLS's motivation and you also understand that I enjoy fooling myself. I doubt that you have any other clue about RLS' motives than your general negativity. And you do understand that your comment can be understood as purposefully insulting me and others? |
|
|
|
Post by mnholdem on Feb 13, 2016 20:17:45 GMT -5
Let me be very clear. The RLS deal is simply a proof of concept deal. RSL wants to see if TS works for one or possibly a few of their drugs. Because no one knows what milestones actually means money for MNKD, this deal is just like the other deals Mannkind struck back in 2014 that didn't have any up front money and were all based on milestone payments. To date, those two deals have amounted to nothing. So while some of you want to feel good about your investigative skills, let me remind you that the odds of Mannkind making anything from the RSL deal are very low. If RLS thought technosphere was the game changer that many of you think it is, it would have proved it by giving MNKD up front cash. Many on here need to stop fooling yourselves. Unfortunately, it is quite obvious that you enjoy doing so. I agree that investors should try not to read more into the RLS deal until we get more information. However I think that you err in stating that it's "simply a proof of concept" deal. While it's true that MannKind's primary responsibility is to bring various proprietary API to the POC milestone, after which Receptor Life Sciences takes over 100% responsibility for FDA trials, the Agreement also gives MannKind royalties on all future drug sales in addition to the $102.5M+ early development milestone payments. It's more than a simple POC deal, even though royalties may be a few years away. Another issue of relevance is what impact the deal may have on Wall Street sentiment once the company and its drug portfolio is made public. "Buy the rumor" may apply if Wall Street likes the company. If there is big money behind RLS it increases the likelihood that RLS can afford the costs of development, including FDA trials. Short term, there's not much to shout about. CEO Pfeffer implied that the first milestone payment may be achieved this year, but "may be" is not as promising as "will be" received. I am eager to hear more information about Receptor, even though we have more important issues related to generating cash, hopefully via initial (and sizeable) stocking orders from countries outside the U.S. as early as 2Q. |
|
|
|
Post by agedhippie on Feb 13, 2016 23:37:33 GMT -5
The TASE maneuver diluted the US stock since it was ordinary common stock that was sold. It was a good plan but incredibly badly executed. This is also what I took away as the original plan: They wanted to sell directly to TASE biotech funds with these funds not being allowed to sell into the US market. So the plan was not to dilute the US market. --- Read more: mnkd.proboards.com/thread/4988/receptor-life-science?page=14#ixzz406gvt2jcWhy was it incredibly badly executed? It did not work well, sure. But why do you blame management. Everything was fine.They went down to Israel, finished paper work, had their speeches and when everyone thought it is done, the regulators stepped in. Then there was, I guess, some panic and last minute arrangements to save face. The issue was the late decision of the regulators. And there was a AF twitter message with a false translation of an article that was later lost.. At the time there were just over 410 million shares outstanding and Mannkind filed to sell another 50 million common stock shares. In the event they only managed to sell part of that pool but that's dilution! So what happened? Management tried to get clever and placed restrictions on the sale. Predictably the regulator objected because this would have prevented the trackers from selling the stock and funds need to be able to do that in order to track their index. The funds decided it was easier to buy on NASDAQ rather than TASE and avoid problems and that's what most did so we ended up raising $30 million rather than $120 million. All because Mannkind management don't understand that trackers have to track. |
|
|
|
Post by boytroy88 on Feb 14, 2016 22:24:12 GMT -5
This is also what I took away as the original plan: They wanted to sell directly to TASE biotech funds with these funds not being allowed to sell into the US market. So the plan was not to dilute the US market. --- Read more: mnkd.proboards.com/thread/4988/receptor-life-science?page=14#ixzz406gvt2jcWhy was it incredibly badly executed? It did not work well, sure. But why do you blame management. Everything was fine.They went down to Israel, finished paper work, had their speeches and when everyone thought it is done, the regulators stepped in. Then there was, I guess, some panic and last minute arrangements to save face. The issue was the late decision of the regulators. And there was a AF twitter message with a false translation of an article that was later lost.. At the time there were just over 410 million shares outstanding and Mannkind filed to sell another 50 million common stock shares. In the event they only managed to sell part of that pool but that's dilution! So what happened? Management tried to get clever and placed restrictions on the sale. Predictably the regulator objected because this would have prevented the trackers from selling the stock and funds need to be able to do that in order to track their index. The funds decided it was easier to buy on NASDAQ rather than TASE and avoid problems and that's what most did so we ended up raising $30 million rather than $120 million. All because Mannkind management don't understand that trackers have to track. I'm sorry...but the deal did not result in any share dilution. At least that's what I'm seeing from Yahoo finance. ycharts.com/companies/MNKD/shares_outstanding |
|
|
|
Post by agedhippie on Feb 15, 2016 0:00:39 GMT -5
At the time there were just over 410 million shares outstanding and Mannkind filed to sell another 50 million common stock shares. In the event they only managed to sell part of that pool but that's dilution! So what happened? Management tried to get clever and placed restrictions on the sale. Predictably the regulator objected because this would have prevented the trackers from selling the stock and funds need to be able to do that in order to track their index. The funds decided it was easier to buy on NASDAQ rather than TASE and avoid problems and that's what most did so we ended up raising $30 million rather than $120 million. All because Mannkind management don't understand that trackers have to track. I'm sorry...but the deal did not result in any share dilution. At least that's what I'm seeing from Yahoo finance. ycharts.com/companies/MNKD/shares_outstandingYou should check Mannkind's SEC filings instead of relying on Yahoo Finance. This is from the 8-K filed November 19, 2015: On November 9, 2015, MannKind Corporation (the “Company”) entered into a series of stock purchase agreements to sell up to an aggregate of 50,000,000 shares of its common stock in a registered direct offering to selected investment funds (the “purchasers”) in Israel that hold securities included within certain stock indexes of the Tel Aviv Stock Exchange (the “TASE”). The 424B5, the filed brochure document for the sale, even includes a section on dilution resulting from this sale as well as dilution resulting from the concurrent warrants that were issued. |
|
|
|
Post by jpg on Feb 15, 2016 0:03:31 GMT -5
At the time there were just over 410 million shares outstanding and Mannkind filed to sell another 50 million common stock shares. In the event they only managed to sell part of that pool but that's dilution! So what happened? Management tried to get clever and placed restrictions on the sale. Predictably the regulator objected because this would have prevented the trackers from selling the stock and funds need to be able to do that in order to track their index. The funds decided it was easier to buy on NASDAQ rather than TASE and avoid problems and that's what most did so we ended up raising $30 million rather than $120 million. All because Mannkind management don't understand that trackers have to track. I'm sorry...but the deal did not result in any share dilution. At least that's what I'm seeing from Yahoo finance. ycharts.com/companies/MNKD/shares_outstandingHahaha! How did they get the little money they got if they didn't sell any shares. |
|
|
|
Post by dictatorsaurus on Feb 16, 2016 9:56:22 GMT -5
Posted on YMB. Can't verify authenticity.
"Quote from Receptor,
"Thank you for your interest in Receptor Life Sciences. We are pleased to be partnering with MannKind to deliver inhaled therapeutics utilizing their innovative platform. Our work is proceeding rapidly and we will look forward to sharing more exciting news with you as our activities become public.
Thank you again,
The Receptor Team"
|
|
Deleted
Deleted Member
Posts: 0
|
Post by Deleted on Feb 16, 2016 10:12:40 GMT -5
Posted on YMB. Can't verify authenticity. "Quote from Receptor, "Thank you for your interest in Receptor Life Sciences. We are pleased to be partnering with MannKind to deliver inhaled therapeutics utilizing their innovative platform. Our work is proceeding rapidly and we will look forward to sharing more exciting news with you as our activities become public. Thank you again, The Receptor Team" I thought this was the auto generated email response. |
|
|
|
Post by dictatorsaurus on Feb 16, 2016 10:16:27 GMT -5
It probably is. But I haven't seen that one yet. So I figured I'd share it.
|
|
|
|
Post by mnholdem on Feb 16, 2016 10:20:26 GMT -5
If you go to www.receptorlife.com/ , click the "Get Notified" square and fill out the Contact Form, the computer-generated message posted above (and apparently at YMB) will appear in your mailbox in a few minutes. 
|
|
|
|
Post by prcgorman2 on Feb 17, 2016 15:09:27 GMT -5
I checked the website, and the domain name in WHOIS. The owner of the domain name used for the website is not shown. It is a shell domain name owning service. The website and the domain name could have been setup by Martin Skreli or other non-friendly, so I didn't elect to fill out their form.
|
|
|
|
Post by cathode on Mar 1, 2016 16:14:54 GMT -5
cgiscgis brought up a new USA trademark for both "Receptor" and "Receptor Life Sciences" "Receptor Life Sciences"ReceptorThere is a nugget (or nug, as the kids say) of information -- Though not definitive, this is support for claims that the API is some sort of cannabis extract.
|
|
|
|
Post by irrationalexubera on Mar 1, 2016 16:32:15 GMT -5
after seeing this, i'm nearly 100% certain that this pertains to weed, and if so, their royalty percentage will pay off big in the years to come as more and more states legalize for medicinal purposes.
way to uh, blaze, the trail MNKD!
|
|
